Ponatinib
- Generic Name
- Ponatinib
- Brand Names
- Iclusig
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F3N6O
- CAS Number
- 943319-70-8
- Unique Ingredient Identifier
- 4340891KFS
- Background
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
- Indication
1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病（CML）；或不能耐受达沙替尼或尼洛替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。
2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病（Ph+ALL）；或不能耐受达沙替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
- Conditions
- Myeloid Leukemia, Chronic, Chronic Phase
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 283
- Registration Number
- NCT02467270
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada
🇬🇧Imperial College Healthcare NHS Trust, London, England, United Kingdom
Retrospective Evaluation of CML Patients in the National Compassionate Program
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 38
- Registration Number
- NCT02448095
- Locations
- 🇮🇹
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy
🇮🇹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano, Milano, Italy
🇮🇹Azienda Ospedaliera "S.Gerardo", Monza, Italy
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2022-01-05
- Target Recruit Count
- 16
- Registration Number
- NCT02398825
- Locations
- 🇮🇹
Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi, Bologna, Italy
🇮🇹Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy
🇮🇹Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto", Catania, Italy
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
- Conditions
- Recurrent Non-small Cell Lung CancerRecurrent Small Cell Lung CancerStage IIIA Non-small Cell Lung CancerAdenocarcinoma of the LungStage IV Non-small Cell Lung CancerExtensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 171
- Registration Number
- NCT01935336
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01888562
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Ariad Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT01874665
- Locations
- 🇺🇸
Oregon Health & Sciences University, Site #048, Portland, Oregon, United States
🇺🇸Fox Chase Cancer Center, Site #012, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Site #047, Boston, Massachusetts, United States
Ponatinib for Advanced Medullary Thyroid Cancer
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- National Institutes of Health Clinical Center (CC)
- Target Recruit Count
- 3
- Registration Number
- NCT01838642
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Ponatinib in Advanced NSCLC w/ RET Translocations
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT01813734
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Ponatinib for Squamous Cell Lung and Head and Neck Cancers
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Cancer
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT01761747
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Ariad Pharmaceuticals
- Target Recruit Count
- 307
- Registration Number
- NCT01650805
- Locations
- 🇺🇸
US Oncology - Providence Health System, Site #167, Burbank, California, United States
🇺🇸UCLA Department of Medicine, Site #027, Los Angeles, California, United States
🇺🇸Seattle Cancer Care Alliance, Site #100, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.